Figure 2 | Scientific Reports

Figure 2

From: A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody

Figure 2

ZGGS15 binds cells expressing LAG-3 and TIGIT with high affinity. CHO cells expressing human LAG-3 (A) or human TIGIT (B) were stained as described in the Methods section. The median fluorescence intensity (MFI) from the AF-647 channel was calculated using FlowJo, and the means of triplicate wells plus their standard deviation were shown. PBMCs were stained as described in the Methods section. Activated CD4 (C) and CD8 (D) T cells were identified as CD25 CD4 double positives or CD25 CD8 double positives that were negative for the NK marker CD335. Each dot corresponds to the average of triplicate measures, and the standard deviation is represented in the error bar.

Back to article page